---

$14.11

+1.9150 ( +15.71% ) 900.1K

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-03-27	Sale	-25534.00	Iwicki Mark T
2024-03-27	Sale	-12767.00	LAPORTE KATHLEEN
2024-03-27	Sale	-161323.00	Kalowski Lee
2024-03-27	Sale	-12767.00	Thistle Mary
2024-03-27	Sale	-12767.00	Lundberg Sven Ante
2024-03-27	Sale	-23530.00	Alloway Paul
2024-03-27	Sale	-6448.00	Michaud Charles Jr
2024-03-27	Sale	-12767.00	Manke Isaac
2024-02-15	Sale	-14280.00	TZIANABOS ARTHUR
2024-01-05	Sale	-7280.00	Alloway Paul